Manufacturing

Nov 01, 2017
BioPharm International
Rinse sample analysis or visual inspection are risk-based approaches that can be correlated to surface cleanliness to replace surface sampling in a biopharmaceutical equipment cleaning process.
Nov 01, 2017
BioPharm International
Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects.
Oct 25, 2017
By BioPharm International Editors
ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.
Oct 25, 2017
By BioPharm International Editors
The M&A advisory firm has developed an interactive map of manufacturing sites to give insight into the market size of global manufacturing.
Oct 25, 2017
BioPharm International
The use of external retainers to enhance the seal between connectors and tubing is an essential component in single-use manufacturing systems.
Oct 24, 2017
By BioPharm International Editors
The API manufacturer has announced that it has completed the expansion of large-scale manufacturing capabilities at its Charles City, Iowa site.
Oct 23, 2017
By BioPharm International Editors
The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.
Oct 23, 2017
By BioPharm International Editors
The clinical-stage biopharmaceutical company has announced the opening of a new gene therapy manufacturing facility in Modiin, Israel, which is anticipated to be the production site of the company’s lead cancer drug candidate.
Oct 23, 2017
By BioPharm International Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By BioPharm International Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
native1_300x100
lorem ipsum